Other mutated genes reported at <5% frequency with uncertain impact on survival include TET2, DNMT3A, NFE2, SH2B3, CUX1, CBL, RUNX1, NOTCH1, N/KRAS and TP53. Myeloid mutations are enriched in patients with cytopenic versus myeloproliferative MF phenotype [33], including HMR and U2AF1 gene mutations (AM Vannucchi et al., 2022, submitted), consistent with prior data indicating clustering with anemia and thrombocytopenia [34]. This evidence concerns the gene U2AF1 and anemia.